Oxurion NV (0G99.L)
| Chiusura precedente | 0,4100 |
| Aperto | 0,4200 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,4080 - 0,4350 |
| Intervallo di 52 settimane | 0,4080 - 0,4350 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 16,873M |
| Beta (5 anni mensile) | 1,09 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7590 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting
Leuven, BELGIUM, Boston, MA, US – JUNE 13, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that two presentations were delivered at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany. The Macula Society presentations are available under Conferences and Events within the Investors section of the Company’s webs
- GlobeNewswire
Oxurion Announces Preclinical Presentation on THR-149 at KININ2022
Leuven, BELGIUM, Boston, MA, US – JUNE 7, 2022 – Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in patients with retinal disorders including diabetic macular edema, today delivered a preclinical presentation evaluating the pharmacokinetic properties of THR-149 at KININ2022, held in Annecy, France, June 5-8, 2022. The KININ2022 presentation is available under Conferences and Events within the Invest
- GlobeNewswire
Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting
Leuven, BELGIUM, Boston, MA, US – JUNE 3, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that two abstracts will be presented at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of diabeti
